
Iovance Biotherapeutics, Inc. – NASDAQ:IOVA
Iovance Biotherapeutics stock price today
Iovance Biotherapeutics stock price monthly change
Iovance Biotherapeutics stock price quarterly change
Iovance Biotherapeutics stock price yearly change
Iovance Biotherapeutics key metrics
Market Cap | 2.27B |
Enterprise value | N/A |
P/E | -2.34 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 1.81 |
PEG ratio | 0.20 |
EPS | -1.8 |
Revenue | 1.90M |
EBITDA | -447.80M |
Income | -449.64M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -23519.12% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeIovance Biotherapeutics stock price history
Iovance Biotherapeutics stock forecast
Iovance Biotherapeutics financial statements
$21.33
Potential upside: 717.36%
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 238K | -106.52M | -44759.66% |
---|---|---|---|
Sep 2023 | 469K | -113.76M | -24255.86% |
Dec 2023 | 482K | -116.37M | -24145.02% |
Mar 2024 | 715K | -112.97M | -15800.84% |
Jun 2023 | 757293000 | 178.72M | 23.6% |
---|---|---|---|
Sep 2023 | 852315000 | 178.30M | 20.92% |
Dec 2023 | 780351000 | 195.73M | 25.08% |
Mar 2024 | 869830000 | 189.80M | 21.82% |
Jun 2023 | -93.95M | -156.77M | 1.02M |
---|---|---|---|
Sep 2023 | -84.08M | -79.01M | 202.8M |
Dec 2023 | -83.97M | -72.84M | 962K |
Mar 2024 | -122.27M | -111.50M | 193.57M |
Iovance Biotherapeutics alternative data
Aug 2023 | 503 |
---|---|
Sep 2023 | 503 |
Oct 2023 | 503 |
Nov 2023 | 503 |
Dec 2023 | 503 |
Jan 2024 | 503 |
Feb 2024 | 503 |
Mar 2024 | 557 |
Apr 2024 | 557 |
May 2024 | 557 |
Jun 2024 | 557 |
Jul 2024 | 557 |
Iovance Biotherapeutics other data
Period | Buy | Sel |
---|---|---|
Feb 2024 | 5282000 | 0 |
Nov 2024 | 0 | 50000 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Option | PURI RAJ K. officer: Chief Regulatory Officer | Restricted Stock Units | 8,334 | N/A | N/A | ||
Option | PURI RAJ K. officer: Chief Regulatory Officer | Common Stock | 8,334 | N/A | N/A | ||
Option | VOGT FREDERICK G director, officer.. | Common Stock | 10,417 | N/A | N/A | ||
Option | VOGT FREDERICK G director, officer.. | Common Stock | 10,417 | N/A | N/A | ||
Option | VOGT FREDERICK G director, officer.. | Restricted Stock Units | 10,417 | N/A | N/A | ||
Option | VOGT FREDERICK G director, officer.. | Restricted Stock Units | 10,417 | N/A | N/A | ||
Option | BILINSKY IGOR officer: Chief Operating Officer | Common Stock | 3,516 | N/A | N/A | ||
Option | BILINSKY IGOR officer: Chief Operating Officer | Restricted Stock Units | 3,516 | N/A | N/A | ||
Option | GRAF FINCKENSTEIN FRIEDRICH officer: Chief Me.. | Common Stock | 3,906 | N/A | N/A | ||
Option | GRAF FINCKENSTEIN FRIEDRICH officer: Chief Me.. | Common Stock | 3,906 | N/A | N/A |
Quarter | Transcript |
---|---|
Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 28 Feb 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
Insider | Compensation |
---|---|
Mr. Jean-Marc Bellemin M.B.A. (1972) Chief Financial Officer & Principal Accounting Officer | $580,000 |
Dr. Friedrich Graf Finckenstein M.D. (1967) Chief Medical Officer | $551,400 |
Dr. Frederick G. Vogt Ph.D., Esq. (1974) Interim Pres, Chief Executive Officer, Gen. Counsel & Corporation Sec. | $515,400 |
Iovance Biotherapeutics: Abysmal Q1 2025 Performance Creates Buying Opportunity
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
Cellectis: 2 Data Readouts Of Blood Cancer Studies By End Of 2024
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts
Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results
Iovance: Approval For Historic Solid Tumor Targeting TIL Therapy Likely, Outlook Promising
Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date
3 Biotech Bull Cases To Consider In 2024 - And 2 Wildcard Recommendations
-
What's the price of Iovance Biotherapeutics stock today?
One share of Iovance Biotherapeutics stock can currently be purchased for approximately $2.61.
-
When is Iovance Biotherapeutics's next earnings date?
Unfortunately, Iovance Biotherapeutics's (IOVA) next earnings date is currently unknown.
-
Does Iovance Biotherapeutics pay dividends?
No, Iovance Biotherapeutics does not pay dividends.
-
How much money does Iovance Biotherapeutics make?
Iovance Biotherapeutics has a market capitalization of 2.27B.
-
What is Iovance Biotherapeutics's stock symbol?
Iovance Biotherapeutics, Inc. is traded on the NASDAQ under the ticker symbol "IOVA".
-
What is Iovance Biotherapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Iovance Biotherapeutics?
Shares of Iovance Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Iovance Biotherapeutics's key executives?
Iovance Biotherapeutics's management team includes the following people:
- Mr. Jean-Marc Bellemin M.B.A. Chief Financial Officer & Principal Accounting Officer(age: 53, pay: $580,000)
- Dr. Friedrich Graf Finckenstein M.D. Chief Medical Officer(age: 58, pay: $551,400)
- Dr. Frederick G. Vogt Ph.D., Esq. Interim Pres, Chief Executive Officer, Gen. Counsel & Corporation Sec.(age: 51, pay: $515,400)
-
How many employees does Iovance Biotherapeutics have?
As Jul 2024, Iovance Biotherapeutics employs 557 workers.
-
When Iovance Biotherapeutics went public?
Iovance Biotherapeutics, Inc. is publicly traded company for more then 14 years since IPO on 15 Oct 2010.
-
What is Iovance Biotherapeutics's official website?
The official website for Iovance Biotherapeutics is iovance.com.
-
Where are Iovance Biotherapeutics's headquarters?
Iovance Biotherapeutics is headquartered at 825 Industrial Road, San Carlos, CA.
-
How can i contact Iovance Biotherapeutics?
Iovance Biotherapeutics's mailing address is 825 Industrial Road, San Carlos, CA and company can be reached via phone at +65 02607120.
-
What is Iovance Biotherapeutics stock forecast & price target?
Based on 3 Wall Street analysts` predicted price targets for Iovance Biotherapeutics in the last 12 months, the avarage price target is $21.33. The average price target represents a 717.36% change from the last price of $2.61.
Iovance Biotherapeutics company profile:

Iovance Biotherapeutics, Inc.
iovance.comNASDAQ
557
Biotechnology
Healthcare
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
San Carlos, CA 94070
CIK: 0001425205
ISIN: US4622601007
CUSIP: 462260100